Practice
Reactivation of hepatitis B virus associated with immunosuppression therapy
Joseph G.H. Lee, Mollie Carruthers and Hin Hin Ko
CMAJ October 29, 2018 190 (43) E1284; DOI: https://doi.org/10.1503/cmaj.180389
Joseph G.H. Lee
Department of Medicine, University of British Columbia, Vancouver, BC
MDMollie Carruthers
Department of Medicine, University of British Columbia, Vancouver, BC
MDHin Hin Ko
Department of Medicine, University of British Columbia, Vancouver, BC
MDData supplements
Online appendix
Related Articles
In this issue
Article tools
Respond to this article
Reactivation of hepatitis B virus associated with immunosuppression therapy
Joseph G.H. Lee, Mollie Carruthers, Hin Hin Ko
CMAJ Oct 2018, 190 (43) E1284; DOI: 10.1503/cmaj.180389
Jump to section
- Article
- Individuals with past hepatitis B virus (HBV) infection on immunosuppressive therapy are at risk of HBV reactivation
- Reactivation of HBV associated with immunosuppression therapy is a preventable cause of morbidity and mortality
- Onset of HBV reactivation is variable
- Multiple factors play a role in the risk of HBV reactivation with immunosuppression therapy
- Prophylactic antiviral therapy should be considered for those who are at moderate or high risk of HBV reactivation
- Acknowledgement
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.